CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...
Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing Alzheimer's symptoms by 50%.
A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback